IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2024 (GlobeNewswire) – Mdxhealth SA (Nasdaq: MDXH), a commercial-stage precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the following investor conferences in June 2024.
William Blair 44th Annual Growth Stock Conference
Presentation: Wednesday, June 5, at 5:00pm ET
Webcast: https://wsw.com/webcast/blair97/mdxh/1942906
Jefferies Global Healthcare Conference
Presentation: Thursday, June 6, at 1:30pm ET
Webcast: https://wsw.com/webcast/jeff302/mdxh/1846928
Live webcasts of the presentations will be accessible on the Investor page of mdxhealth’s website at https://mdxhealth.com/presentations-events/. Replays will be available for up to 60 days following each event.
About mdxhealth®
Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
mdxhealth This email address is being protected from spambots. You need JavaScript enabled to view it. | |
LifeSci Advisors (IR & PR) US: +1 518-221-0106 This email address is being protected from spambots. You need JavaScript enabled to view it. |
NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
Last Trade: | US$1.60 |
Daily Change: | 0.06 3.56 |
Daily Volume: | 15,252 |
Market Cap: | US$79.200M |
February 26, 2025 February 12, 2025 January 13, 2025 November 06, 2024 October 14, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load